<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002222</url>
  </required_header>
  <id_info>
    <org_study_id>268B</org_study_id>
    <nct_id>NCT00002222</nct_id>
  </id_info>
  <brief_title>A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS</brief_title>
  <official_title>An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis&#xD;
      in patients who have been treated for this condition in the past. This study also examines&#xD;
      the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive valganciclovir twice a day for 21 days as induction therapy then daily as&#xD;
      maintenance therapy. Patients are encouraged to remain on study for at least 3 months and&#xD;
      will remain until common study closure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed with caution:&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Famciclovir.&#xD;
&#xD;
          -  Valaciclovir.&#xD;
&#xD;
          -  Imipenem-cilastatin.&#xD;
&#xD;
          -  Myelosuppressive agents.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection with CMV retinitis.&#xD;
&#xD;
          -  Minimum of 4 weeks prior treatment with ganciclovir, foscarnet, or cidofovir.&#xD;
&#xD;
          -  Intraocular implant in either or both eyes, as long as CMV retinitis is active in one&#xD;
             eye, upon approval by Roche.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with any of the following symptoms of conditions are excluded:&#xD;
&#xD;
          -  Active extraocular CMV disease.&#xD;
&#xD;
          -  Severe uncontrolled diarrhea or evidence of malabsorption.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Cidofovir.&#xD;
&#xD;
          -  CMV hyperimmune globulin.&#xD;
&#xD;
          -  Probenecid.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Ocular media opacities (corneal, aqueous, lens, or vitreous) preventing ophthalmologic&#xD;
             retinal assessment.&#xD;
&#xD;
          -  Simultaneous participation in another study (unless approved by Roche).&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  A minimum of 4 weeks treatment with ganciclovir, foscarnet, or cidofovir.&#xD;
&#xD;
          -  Approval required for prior use of investigational anti-CMV agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cornell AIDS Clinical Trials Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <keyword>Cytomegalovirus Retinitis</keyword>
  <keyword>Prodrugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

